216 related articles for article (PubMed ID: 32373967)
1. MiR-142-5p reverses the resistance to gefitinib through targeting HOXD8 in lung cancer cells.
Zhu W; Wang JP; Meng QZ; Zhu F; Hao XF
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4306-4313. PubMed ID: 32373967
[TBL] [Abstract][Full Text] [Related]
2. MiR-145 changes sensitivity of non-small cell lung cancer to gefitinib through targeting ADAM19.
Wang Y; Lian YM; Ge CY
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5831-5839. PubMed ID: 31298334
[TBL] [Abstract][Full Text] [Related]
3. A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells.
Fan D; Yang Y; Zhang W
BMC Pulm Med; 2022 Jan; 22(1):27. PubMed ID: 34996416
[TBL] [Abstract][Full Text] [Related]
4. The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance.
Gong J; He L; Ma J; Zhang J; Wang L; Wang J
J BUON; 2017; 22(2):454-461. PubMed ID: 28534369
[TBL] [Abstract][Full Text] [Related]
5. HOXA4-regulated miR-138 suppresses proliferation and gefitinib resistance in non-small cell lung cancer.
Tang X; Jiang J; Zhu J; He N; Tan J
Mol Genet Genomics; 2019 Feb; 294(1):85-93. PubMed ID: 30196354
[TBL] [Abstract][Full Text] [Related]
6. MiR-195 reverses 5-FU resistance through targeting HMGA1 in gastric cancer cells.
Wang CQ
Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3771-3778. PubMed ID: 31115003
[TBL] [Abstract][Full Text] [Related]
7. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
8. LncRNA HOST2 enhances gefitinib-resistance in non-small cell lung cancer by down-regulating miRNA-621.
Chen ZY; Liu HY; Jiang N; Yuan JM
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9939-9946. PubMed ID: 31799663
[TBL] [Abstract][Full Text] [Related]
9. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
[TBL] [Abstract][Full Text] [Related]
10. MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1.
Jin S; He J; Li J; Guo R; Shu Y; Liu P
Thorac Cancer; 2018 Oct; 9(10):1262-1270. PubMed ID: 30126075
[TBL] [Abstract][Full Text] [Related]
11. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
Sun C; Gao W; Liu J; Cheng H; Hao J
Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
[TBL] [Abstract][Full Text] [Related]
12. Cucurbitacin B enhances apoptosis in gefitinib resistant non‑small cell lung cancer by modulating the miR‑17‑5p/STAT3 axis.
Yu B; Zheng L; Tang H; Wang W; Lin Y
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34396444
[TBL] [Abstract][Full Text] [Related]
13. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
Li Q; Wang Y; He J
J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
[TBL] [Abstract][Full Text] [Related]
14. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
Qi MM; Ge F; Chen XJ; Tang C; Ma J
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
[TBL] [Abstract][Full Text] [Related]
15. MiR-5692a promotes proliferation and inhibits apoptosis by targeting HOXD8 in hepatocellular carcinoma.
Sun S; Wang N; Sun Z; Wang X; Cui H
J BUON; 2019; 24(1):178-186. PubMed ID: 30941968
[TBL] [Abstract][Full Text] [Related]
16. MiR-411-5p acts as a tumor suppressor in non-small cell lung cancer through targeting PUM1.
Xia LH; Yan QH; Sun QD; Gao YP
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(17):5546-5553. PubMed ID: 30229827
[TBL] [Abstract][Full Text] [Related]
17. microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in non-small cell lung cancer.
Liu Y; Miao L; Ni R; Zhang H; Li L; Wang X; Li X; Wang J
Oncol Rep; 2016 Dec; 36(6):3529-3535. PubMed ID: 27748920
[TBL] [Abstract][Full Text] [Related]
18. Circ_0001786 facilitates gefitinib resistance and malignant progression in non-small cell lung cancer via miR-34b-5p/SRSF1.
Ouyang K; Xie D; Liao H; He Y; Xiong H
J Cardiothorac Surg; 2024 Apr; 19(1):178. PubMed ID: 38581057
[TBL] [Abstract][Full Text] [Related]
19. MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway.
Jiang J; Feng X; Zhou W; Wu Y; Yang Y
Oncotarget; 2016 Nov; 7(45):73188-73199. PubMed ID: 27690301
[TBL] [Abstract][Full Text] [Related]
20. [Screening and identification of microRNAs related to acquired gefitinib-resistance in lung adenocarcinoma cell lines].
Qin X; Liu B; Li Y; You J; Zhou Q
Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):478-83. PubMed ID: 21645449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]